The current U.S. Department of Defense (DoD) Smallpox Vaccination Program began on December 13, 2002 , to counter the potential release of variola virus as an act of terrorism against U.S. military forces (1) . Through April 2004, the DoD has immunized over 615,000 personnel. This represents the largest smallpox vaccination program since the eradication of smallpox in 1977 (2) .
Although sporadic cases of myocarditis and pericarditis were reported with various strains of smallpox vaccine (3), these complications were unexpected with the current strain of smallpox vaccine (New York City Board of Health [NYCBOH] strain) (4, 5) . The DoD clinicians detected a statistically elevated rate of myopericarditis above background levels after smallpox vaccination (6, 7) . Between December 2002 and December 2003, a total of 67 cases of myopericarditis within 30 days after smallpox vaccination were identified among 540,824 vaccinees, based on a consensus case definition (8) .
METHODS
Surveillance for adverse events. The DoD Smallpox Vaccination Program emphasized post-vaccination adverseevent surveillance and patient education (1) . Vaccinees received full-strength concentration of smallpox vaccine (Dryvax, Wyeth Laboratories, Marietta, Pennsylvania), which contains the NYCBOH strain. Cases of myopericarditis were detected through surveillance methods previously described (1, 6) . Guidelines were published alerting providers to the diagnostic criteria and encouraging them to report cases using the Vaccine Adverse Event Reporting System. The Vaccine Healthcare Centers Network collected patient data in a centralized registry. Case identification. Cases were classified by a committee based upon surveillance case definitions for myocarditis and (9) . Patients with persistent symptoms were transferred at the discretion of the clinician to regional military tertiarycare hospitals.
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RESULTS
Demographics.
The clinical characteristics of all 67 cases of probable or confirmed post-vaccinial myopericarditis reported among 540,824 total vaccinees are summarized in Table 1 . The cases were predominantly male (n ϭ 66; 98.5%) and Caucasian (n ϭ 60; 89.6%).
Clinical presentation. All 67 cases presented initially with chest pain or substernal pressure. Prodromal symptoms were documented in 61 (91.1%) patients. Fever and chills were noted in 35 (57.4%) patients; myalgias and/or arthralgias in 19 (31.2%) patients; and headache, non-specific viral syndrome, and fatigue reported in 26 (34.4%) patients. Nine patients (14.7%) had no prodromal syndrome until chest pain prompted medical evaluation.
Follow-up data became available on 64 (96%) patients at a mean of 32 Ϯ 16 weeks after presentation (until April 15, 2004) . Two of the other three patients self-reported as healthy but voluntarily separated from military service and declined to return for follow-up care; one patient died during hospitalization. Eight (13%) patients reported continued atypical, non-specific chest discomfort, three (5%) patients reported continued fatigue, and two (3%) reported complaints of headache. Except for the single fatality, in no case did symptoms disqualify patients from continued active military service.
The single fatality occurred 33 days after multiple vaccinations. The case was reviewed by two independent groups of physicians, who judged the fatality as possibly associated with vaccination, although a definitive link to smallpox or any other specific vaccine could not be established (1,10 -13) . Cardiac catheterization. Catheterization with coronary angiography was performed in 29 (43.2%) patients, with none revealing flow-limiting coronary atherosclerotic lesions. The mean left ventricular end-diastolic pressure was 16 Ϯ 5 mm Hg (range 9 to 22 mm Hg). Electrocardiography. Electrocardiography during initial presentation was reviewed in 61 (91.0%) patients. Six other patients did not have available ECG data, because initial treatment was in remote locations. Sinus rhythm was present in all 61 ECGs reviewed, and an identifiable abnormality was evident in 46 (75.4%). The most common abnormalities were ST-segment changes, evident in 40 (65.6%) patients; 5 (8.2%) had normal variant early repolarization as defined by Wang et al. (14) , and T-wave abnormalities were noted in 11 (18.0%) ( two ECGs showed PR depression. Focal ST-segment elevation was more common than diffuse change, with inferior and inferolateral ST-segment elevation accounting for 45% of pathologic changes. Forty-four of the 61 patients were matched with a follow-up ECG (72%). These ECGs, obtained from 20 to 362 days (median 108 days) from initial presentation, revealed normalization of pathologic ST-segment elevation and T-wave inversions in all patients; non-specific changes from initial presentation remained evident in only one patient. Laboratory studies. Cardiac enzymes were elevated in 60 of 61 (98.4%) patients evaluated with this assay. The three cases with troponin-T elevation were excluded from further analysis. Original quantitative laboratory reports (excluding qualitative reports of troponin "positive" or "negative") were available for 54 of 60 cases (81.6%). The mean peak creatine kinase (CK) was 510 IU/l (range 58 to 1,425 IU/l), and mean peak troponin-I was 14.1 ng/ml (range 0.12 to 139.10 ng/ml). Peak CK and troponin-I were collected at a median of 1.5 and 6.9 h, respectively, from presentation with chest pain.
In four cases where myocardial tissue was obtained, there was no evidence of active vaccinia infection by culture or deoxyribonucleic polymerase chain reaction assays. In the three cases of right ventricular biopsy, inflammatory changes were found: one with no clear cellular infiltrate, one with mild lymphocytic infiltrate, and a third with eosinophilic infiltrate predominance (15) . In the fatal case, in which prolonged pulmonary illness preceded cardiac enzyme elevation, postmortem examination revealed epicardial inflammation with eosinophilic predominance, but without histopathologic evidence of myocarditis. Echocardiography. Of 67 patients, 57 (85.1%) were evaluated with echocardiography during acute illness (Table 3) . At follow-up echocardiography (n ϭ 40), at 11 to 362 days (median 102 days) after diagnosis, the mean ejection fraction was 61 Ϯ 4% (range 54% to 75%), with no residual evidence of ventricular dilation, diastolic dysfunction, regional wall motion abnormality, or pericardial effusion. Functional assessment. Graded exercise testing was performed using the Bruce protocol in 41 patients at 18 to 362 days (median 103 days) from the time of diagnosis. The mean exercise duration was 12.2 Ϯ 1.8 min (range 9.0 to 15.5 min). The mean maximum heart rate achieved was 96.0 Ϯ 5.6% age predicted with a rate-pressure product of 30,853 Ϯ 5,203. Testing precipitated no cardiac symptoms or ECG abnormalities. Persistently symptomatic patients. Unlike the objective normalization of cardiac findings at follow-up, 14% of patients reported continued subjective symptoms (Table 4) . No significant difference occurred in follow-up ejection fraction, functional status, or resting ECG abnormalities among these patients, although those with persistent symp- 
DISCUSSION
Clinical myocarditis or pericarditis is an expected rare complication of smallpox vaccination with the NYCBOH strain of vaccinia. All evaluated patients had objective normalization of cardiac function at follow-up. Approximately 20% reported persistent symptoms despite normal testing. Normalization of echocardiography, ECG, and functional status can be expected, even in those with a depressed ejection fraction at presentation. Pericarditis and myocarditis have been reported after other vaccinations, but they are extremely rare events relative to the millions of individuals immunized; most case reports described self-limited and benign conditions (6) . Previous prospective studies identified ECG changes that may have been myocarditis or pericarditis in 1% to 3% of people who received a European strain of vaccinia (3, 5) . Cardiac involvement has similarly been associated with naturally occurring outbreaks of smallpox in the 1960s (1, 6, 7) . Viral myocarditis can mimic acute myocardial infarction (MI) clinically, electrocardiographically, and biochemically as suggested by the high rate of diagnostic coronary angiograms in our young cohort (16, 17) . Coronary events, including angina and MI, have not been causally associated with smallpox vaccination (18, 19) .
Myocarditis can occur after viral, rickettsial, bacterial, and parasitic disease (20) . Whether the underlying myocardial dysfunction in vaccinia-associated myopericarditis is a result of infectious, toxic, or immunologically mediated myocardial damage is unclear. In our four biopsied cases, active vaccinia infection of the heart was excluded. This suggests that vaccinia-associated myopericarditis is immunologically mediated, rather than a result of viral infection of the myocardium. Independent of pathogenesis, the underlying result involves both patchy or diffuse myocytolysis and intense infiltration with inflammatory cellular products (15, 20) . If the pathogenesis represents eosinophilic injury mediated by autoimmune phenomena, corticosteroids may be efficacious in inflammation, although immunosuppressive therapy is generally considered ineffective in the traditional models of viral-induced myocarditis (21, 22) .
The strength of this study lies in the large number of generally healthy people vaccinated and the comprehensive nature of adverse event reporting after smallpox vaccination, both of which contribute to study power. This study does not address the occurrence of subclinical myopericarditis. Further investigation is ongoing to better define potential risk factors for post-vaccinial myopericarditis.
Finally, post-vaccinial myopericarditis should be considered in the differential diagnosis of patients who develop chest pain within 30 days after smallpox vaccination, which can be expected to be self-limited.
